Trending stocks today
Eli Lilly & Co. (LLY-N)
NYSE:LLY
789.12
6.77
(0.87%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
This summary was created by AI, based on 54 opinions in the last 12 months.
Eli Lilly & Co. (LLY) has been a high-performing company over the last two years, particularly in the weight-loss drug market. However, experts are divided on its current valuation, with some suggesting it is overpriced at a high PE ratio and others highlighting the potential for continued growth. The company is known for its strong pharmaceutical offerings and has a promising pipeline for various medical conditions. Overall, there is optimism for the future of the company but caution about its current stock price.
Fantastic company. Leader in diet boom. Very high valuation - would recommend buying on weakness.
He continues to hold. 35x forward PE, 20% growth rate. Earnings and guidance somewhat disappointing. Long term, tremendous growth in obesity-treatment market and diabetes. Short term, watch technicals. Dipped below 200-day MA, but up $13-14 today. If it bounces here, may be attractive for new or additional money.
Got stopped out recently at $840. Below 200-day MA. RSI versus the market has rolled over. Backdrop for the pharma sector is behaving very poorly. He's going to wait and let the traffic clear.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Social media mentions are up 282% in the past 24h.
$838.135
Unknown
They reported a miss. Weight-loss drugs have now swamped the market, thus shrinking margins. They trade at 80x PE vs. pharma's 12-14x. Why own this? Their PE is higher than even NVDA's. Their earlier super growth in GLP drugs is not sustainable.
He's surprised by today's plunge after reporting. A strong buy-the-dip today. He will give it the benefit of the doubt. Revenue growth in recent quarters has been sound.
It will go higher, but not much, and he wouldn't buy it now. Wait for a pullback.
We like LLY as a large pharmaceutical company, with strong sales growth driven by the high demand for its type 2 diabetes and chronic weight management medication. Analyst estimates call for strong forward sales and earnings growth, but a lot of this is priced into its valuation (51X forward earnings). LLY is an $821B market cap company, with strong margins and expected growth rates. It can be a volatile stock, but for a long-term hold, with a growth mindset in mind, we would be comfortable owning LLY today.
Unlock Premium - Try 5i Free
Healthcare space provides nice combination of growth with stability, in case we get into latter stage of economic cycle.
If owned he would trim but also would add on weakness. It is a little larger and more diversified than Novo-Nordisk.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Social media mentions are up 3000% in the past 24h.
$884.885
Unknown
Its moat are these giant factories they're building. It has firepower. Shares are up 52% this year. He remains a fan.
A great company and the leader in GLP drugs, but trades at a high 50x PE.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Social media mentions are up 650% in the past 24h.
$935.610
Unknown
Eli Lilly & Co.(LLY-N) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 26
Neutral - Hold Signals / Votes : 3
Bearish - Sell Signals / Votes : 12
Total Signals / Votes : 41
Eli Lilly & Co.(LLY-N) Frequently Asked Questions
What is Eli Lilly & Co. stock symbol?
Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N
Is Eli Lilly & Co. a buy or a sell?
In the last year, 41 stock analysts published opinions about LLY-N. 26 analysts recommended to BUY the stock. 12 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..
Is Eli Lilly & Co. a good investment or a top pick?
Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..
Why is Eli Lilly & Co. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Eli Lilly & Co. worth watching?
41 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.
What is Eli Lilly & Co. stock price?
On 2024-12-13, Eli Lilly & Co. (LLY-N) stock closed at a price of $789.12.
Don't buy here, even though valuation's come down. Big winner over the last 2 years. High profile, but single drug. Will start to face competition. New US administration may cause uncertainty. He'd rather pick up the laggards on cheap valuations. See his Top Picks.